Amag preps sNDA after Feraheme clears PhIII hurdles

Amag Pharmaceuticals ($AMAG) has received a dose of good news. Its second late-stage study of Feraheme as a treatment for iron deficiency anemia in a population of non-responders hit both primary endpoints, according to the company, laying the foundation for a supplemental NDA. Amag has been undergoing a turbulent time, bidding its CEO and a quarter of its work force goodbye after a proposed buyout of Allos Therapeutics ($ALTH) fell through amid some heated criticism. The biotech is also selling off its manufacturing facility in Cambridge, MA, as it circles its wagons around Feraheme. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.